Chlorotoxin polypeptides and conjugates and uses thereof
Reduced lysine chlorotoxin polypeptides that may be used to generate single species conjugates of chlorotoxin. Conjugates comprising such chlorotoxin polypeptides and pharmaceutical compositions thereof. Methods of using such compositions and/or conjugates.
1. A chlorotoxin polypeptide, wherein the chlorotoxin polypeptide has at least 90% sequence identity with SEQ ID NO: 1, and wherein each lysine residue present in the chlorotoxin polypeptide, except for the lysine residue corresponding to position 27 of SEQ ID NO:1, is blocked from participating in a chemical conjugation reaction by a modification to the lysine residue.
2. The chlorotoxin polypeptide of claim 1 , wherein the modification is a covalent modification or a non-covalent modification.
3. The chlorotoxin polypeptide of claim 2 , wherein the covalent modification is pegylation or methylation.
4. The chlorotoxin polypeptide of claim 1 , wherein at least one blocked lysine residue is modified at the epsilon NH 2 group of the lysine residue.
5. A conjugate comprising the chlorotoxin polypeptide of claim 1 associated with at least one therapeutic agent, at least one detection agent, or combination thereof.
6. The conjugate of claim 5 , wherein the chlorotoxin polypeptide and the therapeutic agent or the detection agent are directly covalently associated.
7. The conjugate of claim 5 , wherein the chlorotoxin polypeptide and the therapeutic agent or the detection agent are covalently associated through a linker.
8. The conjugate of claim 5 , wherein the therapeutic agent is an anti-cancer agent.
9. The conjugate of claim 5 , wherein the therapeutic agent is a member of the group consisting of radioisotopes, prodrug activating enzymes, radiosensitizers, interfering ribonucleic acids (“RNAs”), superantigens, anti-angiogenic agents, alkylating agents, purine antagonists, pyrimidine antagonists, plant alkaloids, intercalating antibiotics, aromatase inhibitors, anti-metabolites, mitotic inhibitors, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones and anti-androgens.
10. The conjugate of claim 5 , wherein the detection agent is a fluorescent label, a radiolabel, a magnetic resonance imaging label, or a combination thereof.
11. A pharmaceutical composition comprising the conjugate of claim 5 and a pharmaceutically acceptable carrier.